Question explored with the scientific record
Is there a link between treatment for NH Lymphoma, or NHLymphoma itself and Alzheimer’s ?
The short version: the evidence you retrieved does not directly test whether non-Hodgkin lymphoma or its treatment raises Alzheimer's risk. The link is plausible on mechanism but unmeasured in the studies at hand.
The evidence you provided covers genetic drivers of NHL [1], neurological complications during childhood NHL treatment [9], and chemotherapy regimens for NHL [3, 4, 6, 7]. None of these studies tracked long-term cognitive outcomes or Alzheimer's disease. The neurological complications study [9] documents acute events like stroke, seizures, and altered consciousness in children with NHL, but that is a different question from late-life dementia.
What the evidence does show is that NHL and its treatments affect the brain directly. CNS involvement is common enough that a conditioning regimen of thiotepa, busulfan, and cyclophosphamide was studied specifically for NHL patients with brain involvement [6]. The neurological complications study found that 14 of 44 children with NHL had acute brain events, including ischemic stroke and cerebral edema [9]. These are acute injuries, not Alzheimer's pathology, but they establish that NHL and its treatments can damage the brain.
The missing piece is long-term follow-up. No study in this set compared cognitive decline or Alzheimer's rates in NHL survivors versus the general population. Given that chemotherapy agents like ifosfamide, carboplatin, and etoposide [3] cross the blood-brain barrier and cause neurotoxicity, and that NHL itself can invade the CNS, a link is biologically plausible. But plausible is not proven.
My call: the evidence does not answer whether NHL or its treatment increases Alzheimer's risk. The mechanism exists but the study that would settle it, a long-term cohort comparing cognitive outcomes in NHL survivors to matched controls, was not in this retrieval. Confidence: not clear.
Sources used 6
-
Integrative genomic analysis identifies novel causal genes of Hodgkin’s and non-Hodgkin’s lymphoma
This study employs integrative genomic analyses, including transcriptome-wide association studies (TWAS), proteome-wide association studies (PWAS), and summary-data-based Mendelian randomization (SMR), to identify novel causal genes associated with Hodgkin's and non-Hodgkin's ly…
DOI: 10.1007/s12672-025-03101-1 -
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival
This study investigates the efficacy and toxicity of a sequential high-dose chemotherapy regimen of ifosfamide, carboplatin, and etoposide with rituximab in patients with relapsed Hodgkin and large B-cell non-Hodgkin lymphoma, finding increased toxicity without improvement in pr…
DOI: 10.1080/10428190902853136 -
Autologous Stem Cell Transplantation (ASCT) with Benda-CV (Bendamustine, Cyclophosphamide, Etoposide) in Non-Hodgkin (non-HO) and Hodgkin (HL) Lymphoma Patients (pts)
This study evaluates the safety and efficacy of a novel conditioning regimen (Benda-CV) for autologous stem cell transplantation in patients with Hodgkin and non-Hodgkin lymphoma, demonstrating promising outcomes and a manageable toxicity profile.
DOI: 10.1016/j.bbmt.2016.12.041 -
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin Lymphoma
This study evaluates the outcomes of 32 patients with primary or secondary CNS involvement by non-Hodgkin lymphoma who underwent autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide conditioning, reporting a 1-year overall survival estimate of 93% a…
DOI: 10.1016/j.bbmt.2011.07.006 -
Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET
This study evaluates the outcomes of patients with aggressive non-Hodgkin lymphoma (NHL) who underwent combined modality treatment based on FDG-PET response, revealing a 90% progression-free survival rate at three years for those with positive interim or post-chemotherapy FDG-PE…
DOI: 10.1016/j.ijrobp.2012.01.060 -
Neurological complication of non Hodgkin lymphoma in childhood: experience from a single center in Turkey
This study reviews the neurological complications associated with childhood non-Hodgkin lymphoma (NHL) based on a retrospective analysis of 44 patients, identifying key symptoms and potential predictors of complications.
DOI: 10.1007/s00381-013-2267-5